Moreover, it should be noted that this study only focused on validating changes in AKT, the downstream molecule of mTOR; future studies are warranted to explore whether PARP3 also influences other mTOR downstream effectors, such as p70S6K, eIF4E, and PKCα, which may contribute to additional functional outcomes in AML pathogenesis. The gene discussed is MTOR; the disease is acute myeloid leukemia.